Recent Research Funding

Tom Russo and Tim Umland.

More than $2 million in annual extramural funding goes to researchers in our division, including Thomas Russo, MD, (left), shown with collaborator Timothy C. Umland, PhD.

Faculty research is supported by extramural funding of more than $2 million annually. The majority of support is derived from national funding agencies such the National Institutes of Health, the Department of Defense and the Veterans Administration.

Alan Lesse, MD

  • BIG DATA SCIENTIST TRAINING ENCHANCEMENT PROGRAM (BD-STEP)-BD-STEP. Alan Lesse (Co-Principal Investigator), Peter Elkin (Co-Principal Investigator). VA and National Cancer Institute. $60,000. 8/1/2015-9/1/2017.

Timothy Murphy, MD

  • Training the Next Generation of Physician Scientists T35 Training Grant. Timothy Murphy (Principal Investigator). NIAID. $242,416. 9/1/2016-6/1/2021.
  • National Center for Advancing Translational Sciences. Timothy Murphy (Principal Investigator), John Canty, Jr. (Contributor). NIH. 9/1/2015-6/1/2020.
  • Clinical and Translational Science Award: Buffalo Clinical and Translational Research Center. Timothy Murphy (Principal Investigator), Margarita Dubocovich (Co-Investigator), Gene Morse (Co-Investigator), Barry Smith (Co-Investigator). National Center for Advancing Translational Sciences. $13,151,902. 8/1/2015-3/1/2019.
  • Persistent H.influenzae in COPD: virulence, vaccines, and antibiotic resistance. Timothy Murphy (Principal Investigator). NIAID. $2,456,267. 9/1/2014-8/1/2018.
  • Moraxella catarrhalis: virulence-based prevention. Timothy Murphy (Principal Investigator). NIDC. $1,605,805. 7/1/2012-6/1/2017.

Thomas Russo, MD

  • DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumannii. Thomas Russo (Co-Principal Investigator). NIH/NIAID. $981,697. 8/1/2018-8/1/2020.
  • Mab Passive Vaccination against Acinetobacter baumannii. Thomas Russo (Co-Investigator). NIH. $491,635. 9/1/2017-8/1/2022.
  • Development of a diagnostic test for hypervirulent Klebsiella pneumoniae. Thomas Russo (Principal Investigator). NIH. $438,625. 3/1/2016-2/1/2019.
  • Development of HTP Assay for Inhibitors of Aerobactin Production(R01AI116998). Thomas Russo (Co-Investigator), Andrew Gulick (Principal Investigator). National Institutes of Health. 2/1/2016-1/1/2019.
  • Development of a HTP Assay for Inhibitors of Aerobactin Production. Thomas Russo (Co-Investigator). NIH. $358,875. 2/1/2016-1/1/2020.

Brahm Segal, MD

  • The Mae Stone Goode Charitable Trust. Brahm Segal (Co-Principal Investigator), Thomas Cimato (Principal Investigator). $100,000. 3/1/2016-3/1/2019.
  • Evaluation of HSCs and MSCs in ovarian cancer (PI: Dr. Thomas Cimato). Brahm Segal (Co-Investigator). Mae Stone Trust. $100,000. 3/1/2016-3/1/2018.
  • Novel Immunological Biomarkers in Ovarian Cancer Prognosis. Brahm Segal (Principal Investigator). NIH. $3,148,229. 6/1/2015-5/1/2020.